Decks cleared for import of Covaxin, Russia's Sputnik V into Brazil

Covaxin

Brazil has cleared the proposal

to import Bharat Biotech's COVID-19 vaccine, Covaxin into the South American country.

National Health Surveillance Agency of Brazil- Anvisa had earlier denied permission to import Covaxin after authorities found that the Indian plant in which the jab was being made did not meet the Good Manufacturing Practice (GMP) requirements.

The Brazilian health regulator also approved another proposal to import Russia's Sputnik V vaccine into that country.

According to Anvisa's approval, Brazil is expected to receive four million doses of Covaxin initially.

After using the authorized doses, the agency will analyse the data for monitoring the use of the vaccine in order to assess the next quantities to be imported.

"Anvisa authorized this Friday the exceptional import of the Covaxin vaccine by the Ministry of Health, for distribution and use under controlled conditions.

The authorization defined amount of 4 million doses , which can be used only under specific conditions... the decision was taken at the 9th Extraordinary Public Meeting of the Collegiate Board," it said in a statement in Portuguese.

All batches to be destined for Brazil must have been manufactured after the adaptations of Good Manufacturing Practices (GMP) implemented by the manufacturer, Bharat Biotech, according to the corrective and preventive action report (Corrective and Preventive Action - CAPA) presented to Anvisa, the regulator said.

On February 26, Bharat Biotech Ltd had said it signed an agreement with the Brazilian government for the supply of 20 million doses of Covaxin during the second and third quarters of 2021.

Announcing the approval of Spuknik V by Brazil on its official twitter page, the Russian vaccine manufacturer said, "#SputnikV will be used in Brazil following ANVISA's approval. Brazil has become the 67th country in the world to authorize Sputnik V.

The Sputnik V team fully answered all questions from ANVISA on the vaccine's efficacy & safety.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel